IVIM Technology

About IVIM Technology

IVIM Technology Inc., established in 2017, operates at the intersection of biotechnology and advanced optical instrumentation, providing sophisticated imaging solutions for preclinical research. The company was founded by Dr. Pilhan Kim, a professor at the Korea Advanced Institute of Science and Technology (KAIST), based on intravital microscopy (IVM) technology developed at KAIST. Dr. Kim, who serves as CEO, has an extensive background in electrical engineering and biophotonics, with postdoctoral experience at Harvard Medical School, which has directly shaped the company's focus on developing advanced in vivo cellular imaging technologies.

The core of IVIM Technology's business is its proprietary All-in-One Intravital Microscopy (IVM) platform, which enables real-time, three-dimensional visualization and tracking of individual live cells within the complex microenvironments of living organisms. This technology provides a cellular-level view of dynamic biological processes, a capability not offered by conventional imaging modalities like MRI or CT. The company has developed a series of integrated confocal, two-photon, and dual-mode microscopy systems (IVM-C, IVM-M, IVM-CM, and smart versions) designed to be compact, automated, and user-friendly for researchers who may not be imaging experts. These platforms are used to analyze disease pathophysiology, monitor drug delivery, and assess the efficacy of novel therapeutics such as cell, gene, and antibody-based drugs.

IVIM Technology's business model encompasses direct equipment sales, the provision of preclinical Contract Research Organization (CRO) services, and the sale of related accessories and reagents like labeled antibodies. This dual approach allows the company to generate revenue from both capital equipment purchases and recurring service contracts. Its client base consists of academic and research institutions, as well as biotechnology and pharmaceutical companies. Notable clients include Harvard University, Johns Hopkins All Children's Hospital, and Sanofi. Having gone public on the KOSDAQ in August 2024, the formerly venture-backed company is focused on global market penetration and expanding its production and R&D capabilities.